Lilly announces new data from two Phase II ramucirumab trials on NSCLC

[News]

Eli Lilly and Company today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC).

More... (http://www.news-medical.net/news/20121001/Lilly-announces-new-data-from-two-Phase-II-ramucirumab-trials-on-NSCLC.aspx)